Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$11.02 USD

11.02
629,121

+0.27 (2.51%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $11.04 +0.02 (0.18%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.

Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings

GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.

Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?

Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?

AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft

AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.

AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates

908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.

Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Tirthankar Chakraborty headshot

4 Must-Buy Stocks for Remarkable Earnings Acceleration

Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).

AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why

AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks.com featured highlights AxoGen, Western Digital and Gen Digital

AxoGen, Western Digital and Gen Digital have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Best Stocks to Buy for Remarkable Earnings Acceleration

Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.